Natsar Pharmaceuticals
Ellicott City, US · Delaware corporation
Natsar Pharmaceuticals is an applied research and drug development company developing RK-33, a first-in-class small molecule inhibitor of the DDX3 RNA helicase for treating cancers such as lung, breast, prostate, sarcoma, and pancreatic tumors, as well as viral infections including SARS-CoV-2 and HIV. The company is preparing to file an IND and move RK-33 into Phase 1 clinical trials.
Founders & leadership
VR
Venu RamaninFounder & Director; Professor, Johns Hopkins University
Reported raises · per SEC filings
Form D private placements$4.2M disclosed across 1 round · 2026
▶$4.2MraisedMay 2026 · 15 investors · PharmaceuticalsRule 506(b)
▶$4.2MraisedMay 2026 · 15 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
- Venu RamanExecutive Officer, Director
- Amount sold
- $4.2M
- Minimum investment
- $1
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Adarx8 shared keywordsADARx is a clinical-stage biopharmaceutical company developing RNA-based medicines using its RNA science expertise and proprietary targeted delivery platforms to silence disease-causing genes. Its pipeline targets chronic conditions including genetic, complement-mediated, cardiovascular, cardiometabolic, central nervous system, and metabolic diseases.
Day One Biopharmaceuticals8 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Samsara7 shared keywordsSamsara Therapeutics develops small-molecule therapeutics that activate autophagy to slow the progression of age-related neurodegenerative diseases such as ALS, Parkinson's, and Charcot-Marie-Tooth disease. It runs an in-house phenotypic screening platform using patient-derived iPSCs to identify and validate autophagy activators for drug discovery.
Ars Pharma7 shared keywordsARS Pharma develops needle-free epinephrine treatments, including neffy, an FDA-approved epinephrine nasal spray for patients and caregivers managing allergic reactions. The company focuses on providing portable, easy-to-use alternatives to needle-based epinephrine delivery.
Companies competing with Natsar Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Natsar Pharmaceuticals do?
- Natsar Pharmaceuticals is an applied research and drug development company developing RK-33, a first-in-class small molecule inhibitor of the DDX3 RNA helicase for treating cancers such as lung, breast, prostate, sarcoma, and pancreatic tumors, as well as viral infections including SARS-CoV-2 and HIV. The company is preparing to file an IND and move RK-33 into Phase 1 clinical trials.
- Who founded Natsar Pharmaceuticals?
- Natsar Pharmaceuticals was founded by Venu Raman.
- How much funding has Natsar Pharmaceuticals raised?
- Natsar Pharmaceuticals has disclosed $4.2M raised across 1 round.
- Where is Natsar Pharmaceuticals headquartered?
- Natsar Pharmaceuticals is headquartered in Ellicott City, US.